Literature DB >> 30115975

PRSS8 suppresses colorectal carcinogenesis and metastasis.

Yonghua Bao1, Yongchen Guo1, Yiqiong Yang1, Xiaonan Wei1, Shanshan Zhang2, Yongmeng Zhang2, Kai Li2, Ming Yuan2, Dongli Guo3, Virgilia Macias4, Xiangdong Zhu1,5, Wei Zhang1,6, Wancai Yang7,8.   

Abstract

The serine protease PRSS8 has shown important physiological and pathological functions, but its roles in cancer initiation and progression are unclear. We developed and dynamically characterized a conditional knockout Prss8fl/fl, p-Villin-Cre+ mouse model. We found that genetic deficiency of the Prss8 gene caused spontaneous colitis and an inflamed rectum at an early age and caused intestinal tumors at a late age, which were linked to increased intestinal cell proliferation and migration but decreased cell differentiation. Increased PRSS8 expression inhibited cancer cell growth and metastasis in nude mice and inhibited cancer cell migration, invasion, colony formation and tumor sphere formation in vitro, but decreased PRSS8 expression facilitated malignancies in vivo and in vitro. Gene profiling on manipulated cancer cells and intestinal epithelial cells of Prss8 mouse models, gene set enrichment analysis and mechanistic studies revealed that PRSS8 targeted the Wnt/β-catenin, epithelial-mesenchymal transition, and stem cell signaling pathways, which were further supported by the results from the TCGA data mining and validated by immunohistochemical staining on colorectal cancer tissue microarrays. In conclusion, PRSS8 is a novel tumor suppressor that plays critical roles in the suppression of colorectal carcinogenesis and metastasis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30115975     DOI: 10.1038/s41388-018-0453-3

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  43 in total

1.  Clonogenic assay of cells in vitro.

Authors:  Nicolaas A P Franken; Hans M Rodermond; Jan Stap; Jaap Haveman; Chris van Bree
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

2.  Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis.

Authors:  Patrick W B Derksen; Xiaoling Liu; Francis Saridin; Hanneke van der Gulden; John Zevenhoven; Bastiaan Evers; Judy R van Beijnum; Arjan W Griffioen; Jacqueline Vink; Paul Krimpenfort; Johannes L Peterse; Robert D Cardiff; Anton Berns; Jos Jonkers
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

3.  Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.

Authors:  Jeff C Liu; Tao Deng; Rajwinder S Lehal; Jinny Kim; Eldad Zacksenhaus
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

Review 4.  Molecular mechanisms controlling E-cadherin expression in breast cancer.

Authors:  Somesh Baranwal; Suresh K Alahari
Journal:  Biochem Biophys Res Commun       Date:  2009-04-18       Impact factor: 3.575

5.  Regulation of prostasin expression and function in the prostate.

Authors:  Li-Mei Chen; Xiaochun Zhang; Karl X Chai
Journal:  Prostate       Date:  2004-04-01       Impact factor: 4.104

6.  HOXA5 Counteracts Stem Cell Traits by Inhibiting Wnt Signaling in Colorectal Cancer.

Authors:  Paloma Ordóñez-Morán; Caroline Dafflon; Masamichi Imajo; Eisuke Nishida; Joerg Huelsken
Journal:  Cancer Cell       Date:  2015-12-14       Impact factor: 31.743

7.  The membrane-anchored serine protease prostasin (CAP1/PRSS8) supports epidermal development and postnatal homeostasis independent of its enzymatic activity.

Authors:  Diane E Peters; Roman Szabo; Stine Friis; Natalia A Shylo; Katiuchia Uzzun Sales; Kenn Holmbeck; Thomas H Bugge
Journal:  J Biol Chem       Date:  2014-04-04       Impact factor: 5.157

8.  Integrated genome-wide analysis of transcription factor occupancy, RNA polymerase II binding and steady-state RNA levels identify differentially regulated functional gene classes.

Authors:  Michal Mokry; Pantelis Hatzis; Jurian Schuijers; Nico Lansu; Frans-Paul Ruzius; Hans Clevers; Edwin Cuppen
Journal:  Nucleic Acids Res       Date:  2011-09-13       Impact factor: 16.971

9.  E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells.

Authors:  U H Frixen; J Behrens; M Sachs; G Eberle; B Voss; A Warda; D Löchner; W Birchmeier
Journal:  J Cell Biol       Date:  1991-04       Impact factor: 10.539

10.  Tumor suppressor PRSS8 targets Sphk1/S1P/Stat3/Akt signaling in colorectal cancer.

Authors:  Yonghua Bao; Kai Li; Yongchen Guo; Qian Wang; Zexin Li; Yiqiong Yang; Zhiguo Chen; Jianguo Wang; Weixing Zhao; Huijuan Zhang; Jiwang Chen; Huali Dong; Kui Shen; Alan M Diamond; Wancai Yang
Journal:  Oncotarget       Date:  2016-05-03
View more
  10 in total

1.  Overexpressed lncRNA LINC00893 Suppresses Progression of Colon Cancer by Binding with miR-146b-3p to Upregulate PRSS8.

Authors:  Jing Zhu; Chao Jiang; Hongxia Hui; Yuan Sun; Mingyue Tao; Yangqing Liu; Xiaoping Qian
Journal:  J Oncol       Date:  2022-05-05       Impact factor: 4.501

2.  The cell-surface anchored serine protease TMPRSS13 promotes breast cancer progression and resistance to chemotherapy.

Authors:  Andrew S Murray; Thomas E Hyland; Kimberley E Sala-Hamrick; Jacob R Mackinder; Carly E Martin; Lauren M Tanabe; Fausto A Varela; Karin List
Journal:  Oncogene       Date:  2020-08-31       Impact factor: 9.867

Review 3.  Cell surface-anchored serine proteases in cancer progression and metastasis.

Authors:  Carly E Martin; Karin List
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

4.  Colorectal Cancer-Associated Smad4 R361 Hotspot Mutations Boost Wnt/β-Catenin Signaling through Enhanced Smad4-LEF1 Binding.

Authors:  Claudia B Lanauze; Priyanka Sehgal; Katharina Hayer; Manuel Torres-Diz; James A Pippin; Struan F A Grant; Andrei Thomas-Tikhonenko
Journal:  Mol Cancer Res       Date:  2021-02-19       Impact factor: 6.333

5.  The Role of Aberrant DNA Methylation in Misregulation of Gene Expression in Gonadotroph Nonfunctioning Pituitary Tumors.

Authors:  Paulina Kober; Joanna Boresowicz; Natalia Rusetska; Maria Maksymowicz; Agnieszka Paziewska; Michalina Dąbrowska; Jacek Kunicki; Wiesław Bonicki; Jerzy Ostrowski; Janusz A Siedlecki; Mateusz Bujko
Journal:  Cancers (Basel)       Date:  2019-10-25       Impact factor: 6.639

6.  The voltage-gated sodium channel Nav1.7 associated with endometrial cancer.

Authors:  Junxiu Liu; Hao Tan; Wancai Yang; Shuzhong Yao; Liang Hong
Journal:  J Cancer       Date:  2019-08-27       Impact factor: 4.207

7.  Regulatory patterns analysis of transcription factor binding site clustered regions and identification of key genes in endometrial cancer.

Authors:  Xiaohan Tang; Junting Wang; Huan Tao; Lin Yuan; Guifang Du; Yang Ding; Kang Xu; Xuemei Bai; Yaru Li; Yu Sun; Xin Huang; Xiushuang Zheng; Qianqian Li; Bowen Gong; Yang Zheng; Jingxuan Xu; Xiang Xu; Zhe Wang; Xiaochen Bo; Meisong Lu; Hao Li; Hebing Chen
Journal:  Comput Struct Biotechnol J       Date:  2022-01-20       Impact factor: 7.271

8.  Knocking down Sterol regulatory element binding protein 2 (SREBF2) inhibits the Serine Protease 8 (PRSS8) /sodium channel epithelial 1alpha subunit (SCNN1A) axis to reduce the cell proliferation, migration and epithelial-mesenchymal transformation of ovarian cancer.

Authors:  Chunyan Cai; Yumei Zhang; Xing Peng
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

9.  Plasma prostasin: a novel risk marker for incidence of diabetes and cancer mortality.

Authors:  Xue Bao; Biao Xu; Iram Faqir Muhammad; Peter M Nilsson; Jan Nilsson; Gunnar Engström
Journal:  Diabetologia       Date:  2022-08-04       Impact factor: 10.460

10.  A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases.

Authors:  Mi Jian; Li Ren; Guodong He; Qi Lin; Wentao Tang; Yijiao Chen; Jingwen Chen; Tianyu Liu; Meiling Ji; Ye Wei; Wenju Chang; Jianmin Xu
Journal:  J Transl Med       Date:  2020-06-12       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.